PARP1 and neoplasm: PARP inhibitors (PARPi) are synthetically lethal in tumours with BRCA mutations or other homologous recombination repair (HRR) defective (HRD) tumours [1, 2], because PARPi cause replication-associated lesions that can only be resolved by HRR [3].